Impax Laboratories (IPXL) Getting Somewhat Favorable Media Coverage, Accern Reports
News headlines about Impax Laboratories (NASDAQ:IPXL) have trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Impax Laboratories earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned news headlines about the specialty pharmaceutical company an impact score of 46.1100275578244 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
A number of analysts have weighed in on IPXL shares. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $62.00 target price (up previously from $10.00) on shares of Impax Laboratories in a research note on Thursday, May 11th. Zacks Investment Research raised shares of Impax Laboratories from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a research note on Tuesday, July 11th. BMO Capital Markets reaffirmed a “hold” rating and set a $16.00 target price on shares of Impax Laboratories in a research note on Friday, June 23rd. Cantor Fitzgerald started coverage on shares of Impax Laboratories in a research note on Friday, June 16th. They set an “overweight” rating and a $20.00 target price on the stock. Finally, Deutsche Bank AG set a $21.00 target price on shares of Impax Laboratories and gave the stock a “buy” rating in a research note on Monday, July 17th. Four analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $17.85.
Shares of Impax Laboratories (IPXL) traded down 3.059% during mid-day trading on Wednesday, hitting $18.225. 574,414 shares of the company traded hands. The firm’s 50 day moving average price is $17.85 and its 200-day moving average price is $14.72. Impax Laboratories has a 1-year low of $7.75 and a 1-year high of $27.29. The stock’s market capitalization is $1.31 billion.
Impax Laboratories (NASDAQ:IPXL) last announced its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.14 by $0.04. Impax Laboratories had a negative net margin of 71.08% and a positive return on equity of 9.05%. The business had revenue of $202.08 million for the quarter, compared to the consensus estimate of $195.62 million. During the same quarter in the prior year, the firm posted $0.21 earnings per share. The business’s revenue for the quarter was up 17.1% on a year-over-year basis. On average, equities research analysts forecast that Impax Laboratories will post $0.70 EPS for the current year.
TRADEMARK VIOLATION WARNING: “Impax Laboratories (IPXL) Getting Somewhat Favorable Media Coverage, Accern Reports” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/08/30/impax-laboratories-ipxl-getting-somewhat-favorable-media-coverage-accern-reports.html.
About Impax Laboratories
Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.
Receive News & Stock Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related stocks with our FREE daily email newsletter.